非酒精性脂肪性肝炎是肝移植受者肝细胞癌的主要病因。 - Suppr

Suppr

超能文献

NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

作者信息

Koh Jia Hong, Ng Cheng Han, Nah Benjamin, Tan Darren Jun Hao, Loomba Rohit, Huang Daniel Q

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.

出版信息

Clin Gastroenterol Hepatol. 2024 Jan;22(1):197-199.e3. doi: 10.1016/j.cgh.2023.05.019. Epub 2023 May 26.

DOI:10.1016/j.cgh.2023.05.019

PMID:37245718

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10939135/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4fb/10939135/fd1dbf6eb1ca/nihms-1971115-f0001.jpg

相似文献

NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Clin Gastroenterol Hepatol. 2024 Jan;22(1):197-199.e3. doi: 10.1016/j.cgh.2023.05.019. Epub 2023 May 26.

Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma.

Transplantation. 2018 Apr;102(4):640-647. doi: 10.1097/TP.0000000000002043.

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.

J Hepatol. 2019 Aug;71(2):313-322. doi: 10.1016/j.jhep.2019.04.011. Epub 2019 May 7.

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. doi: 10.1016/j.cgh.2018.05.057. Epub 2018 Jun 14.

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

Ann Hepatol. 2019 Nov-Dec;18(6):855-861. doi: 10.1016/j.aohep.2019.06.014. Epub 2019 Sep 6.

Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.

World J Gastroenterol. 2016 Feb 28;22(8):2494-502. doi: 10.3748/wjg.v22.i8.2494.

Therapies in non-alcoholic steatohepatitis (NASH).

Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302.

Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.

World J Gastroenterol. 2014 Nov 28;20(44):16464-73. doi: 10.3748/wjg.v20.i44.16464.

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.

Clin Mol Hepatol. 2020 Apr;26(2):196-208. doi: 10.3350/cmh.2019.0012. Epub 2020 Jan 9.

Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.

引用本文的文献

Disparities in liver transplantation for metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma.

World J Transplant. 2025 Sep 18;15(3):101997. doi: 10.5500/wjt.v15.i3.101997.

Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction Associated Steatotic Liver Disease.

Gastro Hep Adv. 2025 Apr 28;4(8):100689. doi: 10.1016/j.gastha.2025.100689. eCollection 2025.

6-Gingerol, an active compound of ginger, attenuates NASH-HCC progression by reprogramming tumor-associated macrophage via the NOX2/Src/MAPK signaling pathway.

BMC Complement Med Ther. 2025 Apr 23;25(1):154. doi: 10.1186/s12906-025-04890-2.

Metabolic dysfunction-associated steatotic liver disease in adults.

Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1.

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on "Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.

Clin Mol Hepatol. 2025 Apr;31(2):654-657. doi: 10.3350/cmh.2025.0133. Epub 2025 Feb 10.

Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050.

JAMA Netw Open. 2025 Jan 2;8(1):e2454707. doi: 10.1001/jamanetworkopen.2024.54707.

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

Clin Mol Hepatol. 2025 Feb;31(Suppl):S228-S254. doi: 10.3350/cmh.2024.0824. Epub 2024 Dec 26.

Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021.

Clin Gastroenterol Hepatol. 2025 Jul;23(8):1346-1355. doi: 10.1016/j.cgh.2024.10.026. Epub 2024 Dec 16.

Understanding the complex macrophage landscape in MASLD.

JHEP Rep. 2024 Aug 23;6(11):101196. doi: 10.1016/j.jhepr.2024.101196. eCollection 2024 Nov.

The Rising Burden of Hepatocellular Carcinoma: Is the Gender Gap Narrowing?

J Clin Transl Hepatol. 2024 Sep 28;12(9):763-764. doi: 10.14218/JCTH.2024.00216. Epub 2024 Aug 7.

本文引用的文献

Global epidemiology of cirrhosis - aetiology, trends and predictions.

Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.

Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.

Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.

Hepatobiliary Surg Nutr. 2022 Feb;11(1):78-93. doi: 10.21037/hbsn-21-350.

UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.

Clin Gastroenterol Hepatol. 2023 Jun;21(6):1475-1484. doi: 10.1016/j.cgh.2022.02.018. Epub 2022 Feb 16.

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.

Cell Mol Gastroenterol Hepatol. 2021;11(5):1313-1325. doi: 10.1016/j.jcmgh.2020.12.009. Epub 2020 Dec 16.

Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019.

JAMA Netw Open. 2020 Feb 5;3(2):e1920294. doi: 10.1001/jamanetworkopen.2019.20294.

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. doi: 10.1016/j.cgh.2018.05.057. Epub 2018 Jun 14.

Survival analysis in the presence of competing risks.

Ann Transl Med. 2017 Feb;5(3):47. doi: 10.21037/atm.2016.08.62.

Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Circulation. 2016 Feb 9;133(6):601-9. doi: 10.1161/CIRCULATIONAHA.115.017719.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验